In vivo anti-influenza virus activity of a zinc finger peptide

被引:24
作者
Judd, AK
Sanchez, A
Bucher, DJ
Huffman, JH
Bailey, K
Sidwell, RW
机构
[1] STANFORD UNIV,BECKMAN CTR,PROT & NUCLE ACID FACIL,SCH MED,PALO ALTO,CA 94304
[2] NEW YORK MED COLL,DEPT MICROBIOL & IMMUNOL,VALHALLA,NY 10595
[3] UTAH STATE UNIV,DEPT ANIM DAIRY & VET SCI,LOGAN,UT 84322
关键词
D O I
10.1128/AAC.41.3.687
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Matrix protein (MI) is a major structural protein of influenza virus, and it inhibits its own polymerase, A 19-amino-acid peptide, corresponding to a zinc finger region of the M1 sequence of influenza virus strain A/PR/8/34 (HIN1), centered around amino acids 148 to 166, was synthesized, This peptide, designated peptide 6, represents a zinc finger which includes a 7-amino-acid loop or finger and a 4-amino-acid tail at the carboxyl terminus, in addition to the 8 amino acids involved in the coordination of Zn, Three experiments were run to evaluate the activity of peptide 6 on infections induced in mice by influenza A/PR/8/34 and A/Victoria/3/75 (H3N2) viruses. Intranasal (i.n.) treatment of the H1N1 virus infection with 30 or 60 mg/kg of body weight/day, three times daily for 5 days, beginning 4 h pre- or 8 h post-virus exposure, was effective in preventing death, reducing the arterial oxygen decline, and inhibiting lung consolidation, Virus titers in the lungs determined on day 5 were reduced by up to 1.5 log(10) in treated groups, but considerable variation in the titers of the recovered virus was seen, The H3N2 virus infection was treated i.n. with 30, 60, or 120 mg of peptide 6/kg/day by using the above-mentioned delayed initiation treatment schedule, and similar protection was seen, although lung virus titers were not reduced in the day-5 assay, Peptide 6 was well tolerated at doses up to 60 mg/kg/day, This zinc finger peptide may provide a new class of antivirals effective against influenza virus.
引用
收藏
页码:687 / 692
页数:6
相关论文
共 25 条
  • [1] *ACIP, 1986, MMWR-MORBID MORTAL W, V35, P317
  • [2] INFLUENZA-VIRUS RNA SEGMENT-7 HAS THE CODING CAPACITY FOR 2 POLYPEPTIDES
    ALLEN, H
    MCCAULEY, J
    WATERFIELD, M
    GETHING, MJ
    [J]. VIROLOGY, 1980, 107 (02) : 548 - 551
  • [3] BUCHER DJ, 1980, J VIROL, V36, P586, DOI 10.1128/JVI.36.2.586-590.1980
  • [4] ARGININE-MEDIATED RNA RECOGNITION - THE ARGININE FORK
    CALNAN, BJ
    TIDOR, B
    BIANCALANA, S
    HUDSON, D
    FRANKEL, AD
    [J]. SCIENCE, 1991, 252 (5009) : 1167 - 1171
  • [5] MOLECULAR-BASIS FOR SPECIFIC RECOGNITION OF BOTH RNA AND DNA BY A ZINC FINGER PROTEIN
    CLEMENS, KR
    WOLF, V
    MCBRYANT, SJ
    ZHANG, PH
    LIAO, XB
    WRIGHT, PE
    GOTTESFELD, JM
    [J]. SCIENCE, 1993, 260 (5107) : 530 - 533
  • [6] Erickson B. W., 1976, PROTEINS, VII, P255
  • [7] PLAQUE INHIBITION ASSAY FOR DRUG SUSCEPTIBILITY TESTING OF INFLUENZA-VIRUSES
    HAYDEN, FG
    COTE, KM
    DOUGLAS, RG
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 17 (05) : 865 - 870
  • [8] EMERGENCE AND APPARENT TRANSMISSION OF RIMANTADINE-RESISTANT INFLUENZA-A VIRUS IN FAMILIES
    HAYDEN, FG
    BELSHE, RB
    CLOVER, RD
    HAY, AJ
    OAKES, MG
    SOO, WJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (25) : 1696 - 1702
  • [9] COMPARATIVE TOXICITY OF AMANTADINE HYDROCHLORIDE AND RIMANTADINE HYDROCHLORIDE IN HEALTHY-ADULTS
    HAYDEN, FG
    GWALTNEY, JM
    VANDECASTLE, RL
    ADAMS, KF
    GIORDANI, B
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1981, 19 (02) : 226 - 233
  • [10] HUFFMAN JN, IN PRESS ANTIVIR CHE